KDM5A and inclusion body myositis: To test the hypothesis that KDM5A may be an upstream regulator of IBM pathology, we next investigated if its inhibition would modulate hallmark pathological features (p62 and APP aggregation) in a previously established IBM‐mimicking cellular model.